NCT06749730View on ClinicalTrials.gov

Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Unresectable Biliary Tract Carcinoma
Interventions
DRUG

Adebrelimab

adepelizumab ,1200mg, q3w

DRUG

Apatinib

apatinib，250mg，QD

DRUG

gemcitabine and cisplatin

cisplatin 25mg/m2，gemcitabine 1000mg/m2 d1,d8，q3w

Trial Locations (1)

Unknown

RECRUITING

HeNan, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV